Aducanumab Approval Decision Delayed: Could This Be Good News?
Amendment Triggered Three-Month Review Extension
Even analysts who still doubt the FDA will approve the anti-amyloid antibody as the first disease-modifying Alzheimer’s treatment said aducanumab’s likelihood of approval has improved.
